Schwartz Investment Counsel Inc. Has $17.38 Million Position in IQVIA Holdings Inc. $IQV

Key Points

• Schwartz Investment Counsel Inc. has reduced its stake in IQVIA Holdings Inc. by 48.3%, now owning approximately $17.38 million worth of shares.
• Insider Eric Sherbet sold 5,800 shares of IQVIA stock at an average price of $190.05, decreasing his ownership by 17.59%.
• Analysts have recently upgraded IQVIA’s stock ratings, with a current average price target of $234.57 and the majority rating it as a Moderate Buy.

Schwartz Investment Counsel Inc. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 48.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 110,290 shares of the medical research company's stock after selling 103,000 shares during the quarter. Schwartz Investment Counsel Inc. owned about 0.06% of IQVIA worth $17,381,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd lifted its stake in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC lifted its stake in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new position in IQVIA in the first quarter valued at approximately $33,000. Trust Co. of Toledo NA OH bought a new position in IQVIA in the second quarter valued at approximately $39,000. Finally, J.Safra Asset Management Corp lifted its stake in IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company's stock valued at $39,000 after buying an additional 169 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on IQV. Hsbc Global Res raised shares of IQVIA from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 9th. Weiss Ratings reissued a "hold (c)" rating on shares of IQVIA in a research report on Wednesday, October 8th. Jefferies Financial Group raised shares of IQVIA from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Truist Financial boosted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $234.57.

IQVIA Stock Performance

NYSE IQV opened at $212.30 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm's fifty day moving average price is $192.05 and its two-hundred day moving average price is $169.60. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $235.32. The firm has a market capitalization of $36.09 billion, a P/E ratio of 30.72, a price-to-earnings-growth ratio of 2.25 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the prior year, the firm posted $2.64 earnings per share. The company's quarterly revenue was up 5.3% compared to the same quarter last year. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.